Bandingkan Harga & Kinerja Bank Maspion Indonesia Tbk. (BMAS) vs Brigit Biofarmaka Teknologi Tbk. (OBAT)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Bank Maspion Indonesia Tbk. dan Brigit Biofarmaka Teknologi Tbk.: Bank Maspion Indonesia Tbk. diperdagangkan di Rp476 (kapitalisasi pasar 8,49 T, volume 24 jam 6,6 rb), sedangkan Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp246 (kapitalisasi pasar 167,37 M, volume 24 jam 71 rb). Perbedaan utamanya: Bank Maspion Indonesia Tbk. jauh lebih besar — sekitar 50,7× kapitalisasi pasar Brigit Biofarmaka Teknologi Tbk., dan Brigit Biofarmaka Teknologi Tbk. lebih aktif diperdagangkan (71 rb vs 6,6 rb). Mana yang lebih baik tergantung tujuan investasimu.
| BMAS | OBAT | |
|---|---|---|
Kapitalisasi Pasar | 8,49 T | 167,37 M |
Volume | 6,6 rb | 71 rb |
Lot | 66 | 710 |
Perputaran | 3,12 jt | 17,51 jt |
Harga Rata-rata | 472,15 | 246,63 |
Nilai Transaksi | 3,12 jt | 17,51 jt |
Harga Ekuilibrium Indikatif | — | 246 |
Volume Ekuilibrium Indikatif | — | 1 |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Bank Maspion Indonesia Tbk.
PT Bank Maspion Indonesia Tbk (the Bank) was established on November 6, 1989 based on Notarial Deed No. 68 of Soetjipto, S.H., which was amended by Notarial Deed No. 49 dated December 5, 1989 of the same notary. The Bank started its commercial operations in 1990. As of December 31, 2012, the Bank has 10 domestic branches, 27 sub-branches, 10 cash offices and 45 Automatic Teller Machines (ATMs) located at Surabaya, Jakarta, Semarang, Denpasar, Medan, Bandung, Makassar, Malang, Solo and Purwokerto.
Selengkapnya di halaman BMAS →Tentang Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Selengkapnya di halaman OBAT →
